Global Point Of Care Diagnostics Market Size, Share, Growth Analysis, By Product type(Glucose Testing, Hb1Ac Testing), By End users(Clinics, Hospitals), By Platform(Lateral flow assay, Dipsticks) - Industry Forecast 2023-2030

To subscribe with us, please complete the form below.

What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

License Type Top market research company in USA

File Type

Analyst Support

$5,300

BUY NOW GET SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

SPEAK TO AN ANALYST

FAQ's

Point Of Care Diagnostics Market was valued at USD 44.9 billion in 2021 and is poised to grow from USD 45.4 billion in 2022 to USD 75.14 billion by 2030, growing at a CAGR of 6.1% in the forecast period (2023-2030).

The global point of care diagnostics market is fragmented in nature. The prominent players operating in the market are constantly adopting various growth strategies to stay afloat in the market. Product launches, innovations, mergers, and acquisitions, collaborations and partnerships, and intensive R&D are some of the growth strategies that are adopted by these key players to thrive in the competitive market. For instance, in December 2018, Anteo Diagnostics (Australia) and Shanghai GeneoDx Biotechnology (China) announced an agreement to market, sell, and distribute Anteo’s range of AnteoBind products in China The key market players are also constantly focused on R&D to supply industries with the most efficient and cost-effective and customized solutions for students. 'Abbott Laboratories', 'Siemens Healthineers AG ', 'PTS Diagnostics', 'Roche Diagnostics (Switzerland)', 'Danaher Corporation (US)', 'Becton, Dickinson and Company (US)', 'Quidel Corporation (US)', 'BioMérieux SA (France)', 'Sysmex Corporation (Japan)', 'Thermo Fisher Scientific Inc. (US)', 'Johnson & Johnson (US)', 'bioMérieux SA (France)', 'Nova Biomedical (US)', 'Alere Inc. (US)', 'Beckman Coulter, Inc. (US)', 'Hologic, Inc. (US)', 'Cepheid (US)', 'Ortho Clinical Diagnostics (US)', 'Bio-Rad Laboratories, Inc. (US)', 'Trividia Health (US)', 'Chembio Diagnostic Systems, Inc. (US)'

North America emerges as the dominating region in the global point-of-care diagnostics market. The country boasts a robust healthcare system, advanced infrastructure, and a strong presence of key market players. The United States has been at the forefront of point-of-care diagnostics, with significant investments in research and development, resulting in the development of innovative technologies and solutions. The country's large population, high healthcare expenditure, and favourable reimbursement policies have contributed to the dominance of the United States in this market. Moreover, the early adoption of point-of-care diagnostics in various healthcare settings, including hospitals, clinics, and home care, has further solidified its position as the leading region in the global market.

Feedback From Our Clients

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Global Point Of Care Diagnostics Market Size, Share, Growth Analysis, By Product type(Glucose Testing, Hb1Ac Testing), By End users(Clinics, Hospitals), By Platform(Lateral flow assay, Dipsticks) - Industry Forecast 2023-2030

To subscribe with us, please complete the form below.

What people say about us!

Want to customize this report?

FAQ's

What is the global market size of Point Of Care Diagnostics Market?

Who are the key vendors in the Global Point Of Care Diagnostics Market?

What is the key driver of Global Point Of Care Diagnostics Market?

What is the key market trend for Global Point Of Care Diagnostics Market?

Which region accounted for the largest share in Global Point Of Care Diagnostics Market?

Related Reports

Feedback From Our Clients

$5,300